Medicalook
Medicalook

Emtricitabine

http://www.medicalook.com
Emtricitabine

Emtricitabine review





The drug emtricitabine is a treatment to lessen the risk of contracting further infections and subsequent complications because of the presence of the Human Immunodeficiency Virus in select individuals. In a direct description of its mechanism of action, it prohibits the proper transcription of genetic data in the nucleus area.

As an analogue of the genetic component cytidine, it stops the enzyme reverse transcriptase from copying the tarnished RNA code into a newly formed viral DNA. This cessation of normal cellular process lessens the production of potential HIV existing. This has a reverse effect on the creation rate of immune system cells referred to as T cells. With the increased amount of T cells, immune systems have a bigger chance of deflecting pathological attacks as well developing a serious sickness.

It was first approved for public use in July of 2003 as an original compound medication with other retroviral agents. It sought development as in 2005; it was given a safety signal to be used on pediatric patients. It was found out that medication regime for pediatric patients were more effective at 24 to 48 weeks post birth as compared to a similar drug stavudine.

The drug is a prescription drug used solely upon the requirement of the physician. It has been found out that the drug can cause serious liver injury because of its potency and strength. There is an increased risk of lactic acidosis buildup that may be potentially poisonous to the system

Emtricitabine is optimally prescribed for adult treatment of HIV requiring recombined agents. This is given after a primary test of plasma HIV RNA levels. Using two agents, emtricitabine and tenofovir, the drug itself is not a direct cure for the currently existing HIV virus, but rather as a means to effectively curb the chances of letting opportunistic complications such as cancer and super infection by local bacteria.

The drug is administered through the mouth with or without requirement of having to eat anything prior to it. Emtricitabine is readily marketed in 200-milligram tablets. Its usual dosage for adults is 1 tablet daily, at anytime as the patient prefers.

As for pediatric patients aged more than three months, it is safe to compute the drug dose as 6 milligrams per body weight in kilogram, with a maximum of 240 milligrams on a single daily dose.

There are common side effects that are only mild in nature but should be regarded with utmost focus and attention nonetheless. These are episodes of headaches and nausea, diarrhea, joint pains, runny nose, slight depression, sleep disorders, and slight changes in skin color.

There are also serious side effects such as fever, cough, sore throat, and actual super infections of susceptible bacteria. Any of these signs are grounds for a quick call to the physician and immediate countermeasure.

There are several special precautions in administering this drug to patients. First is to determine of any sensitivity to the drug.

It is also very important that emtricitabine be given with precautions when patient is having other medications such as lamivudine and the like, as this may cause a cancellation of effects or nothing added at all.

Emtricitabine has the following structural formula:

Chemical structure of emtricitabine


• Molecular formula of emtricitabine is C8H10FN3O3S
• Chemical IUPAC Name is 4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-pyrimidin-2-one
• Molecular weight is 247.248 g/mol
Emtricitabine available : 200mg tablets

Brand name(s): Coviracil, Emtriva, Racivir, Sustiva, Truvada

  Your Emtricitabine review